Earnings above the baseline
UnitedHealth shares rose 2.2% to $386.90 in premarket trading after its third-quarter results. Reuters cited an LSEG consensus of $4.14 in adjusted earnings per share; the company delivered $4.69. The price move and earnings surprise point in the same direction, but one premarket observation cannot identify what motivated the buyers.[1]
Annual guidance supplies a stronger fundamental anchor. The company raised its adjusted earnings floor to $20.50 per share; Reuters put the previous range at $19.50–$20 and analyst consensus at $19.86. The new floor stands above that consensus. For a long-term owner, the change is a higher management commitment for the whole year alongside a strong quarter. It remains guidance, rather than realized annual earnings.[1]
Those gaps make an expectations-based reading of the gain plausible. I would not turn that into a finding of durable repricing. Position adjustments before the open could produce the same move, and there is no volume or holder-position evidence here. The earnings surprise supplies an economic anchor for the price reaction; the reaction does not establish the durability of the earnings improvement.[1]
Two contributions to medical costs
Medical costs as a share of premiums fell from 89.9% to 88.4%. UnitedHealth highlights pricing discipline, benefit changes and cost management. The ratio also includes $610 million of favorable reserve development for services provided earlier in 2026. Lowering previously expected costs benefits the current quarter’s earnings. There is no basis for assuming that an equivalent benefit repeats every new quarter.[1]
Recognizing the reserve benefit also leaves room for an operating recovery. Pricing and care changes may have produced a better cost structure. The competing explanation is that a material part of the reported improvement reflects revisions to earlier cost estimates. The distinction matters for long-term owners: correcting an earlier estimate raises profit, while sustainable margins on new policies represent a different source of earning capacity.[1]
Operating cash flow of $5.1 billion was 1.2 times net income. There is cash generation in this quarter, but the aggregate cash figure does not isolate the repeatable part of the medical cost ratio. The useful next comparison is the size of reserve benefits alongside that ratio in subsequent results. A low ratio accompanied by a smaller reserve contribution would strengthen the operating-recovery interpretation. The distance between expectations carried by the price gain and repeatable earnings remains unresolved.[1]